Artisan International Small-Mid Fund Q3 2025 Contrarianism Pays Off

Artisan Partners emphasizes a contrarian investment approach, highlighting purchases of Insulet (PODD), added exposure to ConvaTec (CNVVY), a timely buy of SolarEdge around political developments, and a defense of WNS as a business-process outsourcer that has deployed AI to automate customer tasks. The note serves as a firm profile of Artisan's autonomous investment teams and their strategy of identifying mispriced opportunities rather than following narrow market leadership.

Analysis

Market structure: Insulet (PODD) and SolarEdge (SEDG) are structurally advantaged if investors reprice beyond headline GLP‑1 fears and policy noise. PODD benefits from recurring-parts/subscription revenue and closed-loop insulin tech serving ~5–10% of diabetic population (Type‑1), preserving pricing power even as GLP‑1 expands; SEDG benefits from secular residential PV+storage growth and inverter concentration (top suppliers) that support 10–20%+ TAM growth in many scenarios over 3–5 years.

Risk assessment: Key tail risks are regulatory (CMS reimbursement change for pumps within 30–90 days), trade/tariff actions on Chinese components (90–180 days), and product/recall operational shocks; short-term headline volatility likely (days–weeks) around earnings and policy announcements while structural demand plays out over quarters. Hidden dependencies include Asian supply chains for inverters and battery semiconductors and payer economics for insulin supplies; monitor component lead times and inventory-to-sales ratios as leading indicators.

Trade implications: Tactical: establish modest long exposure to PODD (2–3% NAV) and SEDG (1–2% NAV) with concentrated options overlays to define downside; use 4–9 month call spreads on PODD (buy ATM, sell 15–25% OTM) to target 30–60% asymmetric upside while capping premium, and 9–12 month LEAP calls or buy-write on SEDG to capture policy-driven rerating. Consider a relative-value pair: long PODD (2% NAV) vs short LLY/NVO (1–1.5% NAV) to isolate pump re‑rating versus GLP‑1 multiple expansion.

Contrarian angles: The market is underestimating recurring revenue resilience in devices and overestimating GLP‑1 cannibalization of pump demand — mispricing could compress as early as next 1–3 quarters when adoption metrics and subscription ARR show stability. Conversely, political headlines on solar are noisy; a 10% pullback in SEDG on a negative trade headline could create a 6–12 month buying opportunity rather than signal secular demand failure; counterscenario: CMS or tariffs create permanent margin pressure, so size positions accordingly.

Key Decisions for Investors

• Establish a 2–3% NAV long position in PODD within 2–6 weeks, using a 4–9 month call spread (buy near-ATM, sell 15–25% OTM) to cap premium; target 30–60% upside, stop-loss at -25% absolute on the synthetic position.
• Initiate a 1–2% NAV long position in SEDG, prefer 9–12 month LEAP calls or a buy-write to collect premium; only add incrementally on a >10% pullback or after a favorable US policy headline (monitor within next 2–8 weeks).
• Run a pair trade: long PODD 2% NAV vs short LLY or NVO 1–1.5% NAV for 3–6 months to hedge market risk and isolate device re‑rating; cover/reevaluate on earnings or if GLP‑1 sales growth >+25% y/y persists.
• Monitor specific catalysts in next 30–90 days and act: (a) CMS reimbursement notices for insulin pumps — if language tightens, reduce PODD exposure by 50%; (b) US trade/tariff announcements affecting Chinese inverters — if punitive tariffs >10% imposed, trim SEDG to <1% NAV and pivot to diversified BOS suppliers.